Effect of Short Term High Dose Oral Vitamin D Therapy on the Inflammatory Markers in Patients with COVID 19 Disease

Maheshwar Lakkireddy, Srikanth Goud Gadiga, R. Malathi, Madhu Latha Karra, Issv Prasad Murthy Raju, Ragini, Sangeetha Chinapaka, Sai Baba KSS, Manohar Kandakatla
{"title":"Effect of Short Term High Dose Oral Vitamin D Therapy on the Inflammatory Markers in Patients with COVID 19 Disease","authors":"Maheshwar Lakkireddy, Srikanth Goud Gadiga, R. Malathi, Madhu Latha Karra, Issv Prasad Murthy Raju, Ragini, Sangeetha Chinapaka, Sai Baba KSS, Manohar Kandakatla","doi":"10.26502/acbr.50170273","DOIUrl":null,"url":null,"abstract":"Introduction: COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the effect of short term high dose vitamin D therapy in reducing the inflammatory markers of COVID-19. Materials and Methods: Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0 th day and 9 th / 11 th day as per their respective BMI category. Subjects were allotted to VD and NVD groups. VD group received Pulse D therapy (a short term high dose supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Results: Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 15 ng/ml to 81 ng/ml in VD group and highly significant (p<0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p>0.05). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p<0.01). Conclusions: Therapeutic improvement in vitamin D to 80-100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive short term high dose vitamin D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of clinical and biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/acbr.50170273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the effect of short term high dose vitamin D therapy in reducing the inflammatory markers of COVID-19. Materials and Methods: Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0 th day and 9 th / 11 th day as per their respective BMI category. Subjects were allotted to VD and NVD groups. VD group received Pulse D therapy (a short term high dose supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Results: Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 15 ng/ml to 81 ng/ml in VD group and highly significant (p<0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p>0.05). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p<0.01). Conclusions: Therapeutic improvement in vitamin D to 80-100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive short term high dose vitamin D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
短期大剂量口服维生素D治疗对新冠肺炎患者炎症标志物的影响
导语:已知COVID - 19会导致免疫失调,维生素D是已知的免疫调节剂。本研究旨在客观探讨短期高剂量维生素D治疗对降低COVID-19炎症标志物的作用。材料与方法:在第0天和第9 / 11天,根据各自的BMI分类,评估COVID-19合并维生素D缺乏症患者的炎症标志物(N/L比值、CRP、LDH、il - 6、铁蛋白)和维生素D。受试者被分为VD组和NVD组。VD组在标准治疗的基础上接受脉冲D治疗(根据他们的BMI,短期高剂量补充60000国际单位的维生素D,持续8天或10天)。NVD组单独给予标准治疗。分析两组间变量的差异有无统计学意义。结果:130名受试者中有87人完成了研究(VD:44, NVD:43)。VD组维生素D水平由15 ng/ml升高至81 ng/ml,且极显著(p0.05)。两组间(NVD vs VD)标志物减少量差异极显著(p<0.01)。结论:维生素D治疗改善至80-100 ng/ml可显著降低与COVID-19相关的炎症标志物,且无任何副作用。因此,可以安全地将短期高剂量维生素D辅助治疗添加到现有的COVID-19治疗方案中,以改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Herb Stevia Rebaudiana’s Functionalities, Safety, and Applications: A Review Strict Lockdown versus Flexible Social Distance Strategy for COVID-19 Disease: a Cost-Effectiveness Analysis. Prevalence, Trends, and Harm Perception Associated with E-Cigarettes and Vaping among Adolescents in Saudi Arabia. Rapid Real-time Squiggle Classification for Read until using RawMap. Comparative Analysis of Global Hepatic Gene Expression in Adolescents and Adults with Non-alcoholic Fatty Liver Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1